These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32592044)

  • 1. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
    Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
    Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer.
    Lee W; Oh M; Kim JS; Sung M; Hong K; Kwak BJ; Park Y; Jun E; Song KB; Hwang DW; Lee JH; Yoo C; Kim KP; Park I; Jeong JH; Chang HM; Ryoo BY; Lee JB; Kim SC
    Int J Surg; 2024 Jul; 110(7):4074-4082. PubMed ID: 38537071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study.
    Yamada S; Hashimoto D; Yamamoto T; Yamaki S; Oshima K; Murotani K; Sekimoto M; Nakao A; Satoi S
    Pancreatology; 2024 Jun; 24(4):592-599. PubMed ID: 38548551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer.
    Okada K; Uemura K; Kondo N; Sumiyoshi T; Seo S; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Murakami Y; Takahashi S
    Langenbecks Arch Surg; 2022 Mar; 407(2):623-632. PubMed ID: 34609618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy.
    Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Todaka A; Fukutomi A; Uesaka K
    Pancreatology; 2021 Dec; 21(8):1451-1459. PubMed ID: 34462214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
    Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
    Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.
    Williams JL; Kadera BE; Nguyen AH; Muthusamy VR; Wainberg ZA; Hines OJ; Reber HA; Donahue TR
    J Gastrointest Surg; 2016 Jul; 20(7):1331-42. PubMed ID: 27114246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
    Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
    Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic cancer.
    Akita H; Mukai Y; Kubo M; Takahashi H; Hasegawa S; Kitakaze M; Matsuura N; Masuike Y; Sugase T; Shinno N; Kanemura T; Hara H; Sueda T; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Wada H
    Surgery; 2024 Oct; 176(4):1215-1221. PubMed ID: 39079828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Okada K; Takahashi S; Sueda T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):801-811. PubMed ID: 28314992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
    Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
    Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution.
    Masui T; Nagai K; Anazawa T; Sato A; Uchida Y; Nakano K; Yogo A; Kaneda A; Nakamura N; Yoshimura M; Mizowaki T; Uza N; Fukuda A; Matsumoto S; Kanai M; Isoda H; Mizumoto M; Seo S; Hata K; Taura K; Kawaguchi Y; Takaori K; Uemoto S; Hatano E
    BMC Cancer; 2022 Jan; 22(1):119. PubMed ID: 35093003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
    Fisher AV; Abbott DE; Venkatesh M; Leverson GE; Campbell-Flohr SA; Ronnekleiv-Kelly SM; Greenberg CC; Winslow ER; Weber SM
    Ann Surg Oncol; 2018 Sep; 25(9):2661-2668. PubMed ID: 30003452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.
    Miura JT; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Oshima K; Christians KK; Evans DB; Tsai S
    Surgery; 2015 Dec; 158(6):1545-55. PubMed ID: 26243342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of resectability status in neoadjuvant treatment for pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):563-70. PubMed ID: 25921623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis.
    Ye C; Sadula A; Ren S; Guo X; Yuan M; Yuan C; Xiu D
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):731-740. PubMed ID: 33047181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.